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40-word summary: “The prevalence of NTM infection is increasing in children and young people with 
cystic fibrosis - there is an urgent requirement to establish the most effective strategies to prevent 
and treat NTM infection in the paediatric age group.” 
 
Running title: NTM infection in children with CF 
 
ABSTRACT  
Background: Infection with nontuberculous mycobacteria (NTM) is of growing clinical concern in 
people with cystic fibrosis (CF). The epidemiology of infection in children and young people remains 
poorly understood. We wished to investigate the epidemiology of NTM infection in the paediatric 
age-group using data from the United Kingdom CF  Registry. 
Methods: Data from 2010-2015 for children and young people aged <16 years (23,200 observations 
from 5,333 unique individuals) were obtained. Univariate analysis of unique individuals comparing 
all key clinical factors and health outcomes to NTM status was performed. Identified significant 
factors were used to generate a multivariate logistic regression model, which following step-wise 
removal generated a final parsimonious model. 
Results: The prevalence of individuals with a NTM positive respiratory culture increased every year 
from 2010 (45 [1.3%]) to 2015 (156 [3.8%]). Allergic bronchopulmonary aspergillosis (OR 2.66, P = 
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5.0x10-8), age (OR 1.08, P = 3.4x10-10) and intermittent Pseudomonas aeruginosa infection (OR 1.51, 
P = 0.004) were significantly associated with NTM infection. 
Conclusions: NTM infection is of increasing prevalence in the UK paediatric CF population. This study 
highlights the urgent need for work to establish effective treatment and prevention strategies for 
NTM infection in young people with CF. 
Key words: Cystic fibrosis; nontuberculous mycobacteria; children; NTM; epidemiology. 
 
INTRODUCTION 
 
Over 10,000 individuals have cystic fibrosis (CF) in the United Kingdom (UK) making it the most 
common inherited life-limiting condition.[1] More than 4,000 are children or young people under 
the age of 16.[1] The CF Trust maintains a detailed UK patient registry that records anonymised 
clinical data and health outcomes.[2] The registry is updated annually and captures information that 
covers over 90% of people with CF nationally.[1, 2] Despite the development of specialist care and 
incremental improvements in survival, lung disease still accounts for the substantial majority of 
morbidity and premature mortality in people with CF.[3] Susceptibility to respiratory infection with 
particular microbes is a key component of the pathology of CF lung disease and approaches that 
target the treatment or prevention of infection are a mainstay of clinical management.[3] 
Infection with nontuberculous mycobacteria (NTM) has become a subject of increasing clinical 
concern in people with CF over the last 5 years.[4] NTM are environmental organisms found 
commonly in soil and water. Two groupings are most frequently isolated from people with CF, 
Mycobacterium abscessus complex and M. avium complex. Infection with M. abscessus specifically 
has been found to be associated with increased decline in lung function.[5, 6] Treatment of airway 
infection with NTM requires prolonged courses of multiple antibiotics, often for over 12 months, and 
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is associated with a significant treatment burden and frequent adverse effects.[4, 7] Furthermore, 
M. abscessus infection is regarded as a relative contraindication to lung transplantation in many 
centres.[8] There is also emerging evidence to suggest transmission of M. abscessus between 
individuals with CF.[9, 10] 
There are varying estimates of the prevalence of NTM isolation in respiratory samples from people 
with CF that range from 3.7% in parts of Europe to 14% in the United States (US). [11, 12] Several 
reports have suggested an increasing prevalence over the last decade above that accounted for by 
improved screening and detection techniques.[5, 13-16] A previous European registry study of a 
combined adult and paediatric CF population identified age, allergic bronchopulmonary aspergillosis 
(ABPA), Stenotrophomonas maltophilia infection and use of bronchodilators, inhaled antibiotics or 
rhDNase to be associated with NTM infection.[17] Specific knowledge of the epidemiology of NTM 
infection in children and young people with CF is particularly limited at present. Paradoxically it is in 
the paediatric age group where interventions and strategies to treat or prevent infection with NTM 
are likely to yield the greatest clinical benefits. 
We analysed data from the UK CF registry to investigate the epidemiology of NTM infection in 
children and young people under the age of 16 between 2010 and 2015. This included trends in the 
prevalence of NTM infection, individual species isolated, demographic and clinical ‘risk factors’ in 
individuals isolating NTM, along with longitudinal analyses. This data and analyses will inform future 
clinical research relating to NTM infection in children and young people with CF.  
 
METHODS 
Clinical Data and Research Ethics  
Annual review data submitted to the UK CF Registry database between 2010 and 2015 for patients 
up to the age of 16 (23,200 observations from 5,333 unique individuals) were obtained. 
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Supplementary Table 1 lists the variables obtained. Data lacking a unique identifying code, were 
excluded from the analysis (n=38). 
Explicit written consent is obtained from individuals or their parents or guardians for their inclusion 
in the UK CF Registry. The registry is compliant with UK data protection legislation and subject to 
continued Research Ethics Committee approval. Data for this study were obtained by application to 
the CF Trust Research Registry Committee, who approved the application and released anonymised 
data in line with the existing registry ethics approvals.  
 
Data Analysis 
The data were firstly cleaned and checked for duplicates. For each individual NTM positive status 
was defined using the specific registry field which is returned if an individual has had a positive NTM 
culture in the preceding year. Intrinsically, this was not whether an individual met the criteria for 
NTM related pulmonary disease (NTM-PD) but purely whether they had a positive culture in that 12-
month period.[18] In the 2014 and 2015 registry censuses this field was expanded to collect more 
detailed data about NTM status including species, date of culture and treatment data. Individuals 
were tracked through the time period using their unique registry ID.  
All unique individuals were then pooled for analysis of epidemiological risk factors predictive of NTM 
status. These included demographics (age, sex, anthropometric measurements), CFTR genotype, 
lung function, other respiratory microbiological status (P. aeruginosa, Staphylococcus aureus and 
Burkholderia cepacia – S. aureus and P. aeruginiosa were subdivided in to 3 states – negative, 
intermittent - defined as 1-2 isolations in the last year or chronic - defined as 3 or greater isolations 
in the last year) and co-morbidities (CF-related diabetes or ABPA).  
Following a standard approach, univariate non-parametric tests were used to assess predictive value 
and all significant predictors were then included in a multivariate logistic regression model. Step-
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wise removal of non-significant factors was then undertaken to generate the final parsimonious 
model presented. For variables with multiple categorical states included in the multivariate model, 
e.g. P. aeruginosa status, an overall effect was estimated using the Wald test.   
Next, the progress of patients NTM status was tracked over the whole time period to generate 
annual incidence, prevalence and potential response to treatment estimates. For patients who 
remained NTM positive or NTM negative for the duration of the study period, only their latest time 
point was included for analysis. Those with multiple classifications, i.e. those who developed or were 
cleared of NTM infection during the study period, were classified as NTM positive and data from 
their latest NTM positive time point was included for analysis.  
Finally, descriptive data on NTM species and treatment were collated and explored for the 2014 and 
2015 data extracts. All analyses were carried out using Microsoft Access 365, GraphPad Prism 6.05 
and R 3.4.1 using the nlme package.[19] 
RESULTS 
The prevalence of individuals aged 16 years and under with a positive respiratory culture for NTM 
increased year on year between 2010 and 2015 
The prevalence of individuals with a NTM positive respiratory culture in the UK CF Registry aged 16 
and under increased every year from 2010 (45 [1.3%]) through to 2015 (156 [3.8%]) (Figure 1). An 
especially large increase in cases was observed between 2013 (83 [2.1%]) and 2014 (140 [3.6%]). 
Following the pooling of yearly cohorts the number of overall unique NTM cases was identified (288 
from 5,333 [5.4%]). 
Age, P. aeruginosa and ABPA are associated with NTM positive status 
Table 1 summarises the differences between those children and young people who had an NTM 
positive respiratory culture and those that did not. On average children who isolated NTM were 
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older (median 10 years vs. 6 years, P = 2.2 x 10-16), were more likely to be positive for P. aeruginosa 
(45% vs 30%, P = 0.013), B. cepacia (2.4% vs 0.9%, P = 0.013) and to have ABPA (17% vs 4.7%, P = 2.2 
x 10-16).  
No gender difference was seen, nor was a difference between F508del (c.1521 1523del) 
homozygotes or heterozygotes. Heterozygosity for the W1282X (c.3846G>A) mutation was 
statistically significantly associated with positive NTM status. However, given the scarcity of this (21 
heterozygotes) and other rare mutations in the dataset the chance of statistical error was deemed 
too great for further analysis.  
While on average individuals who had a respiratory culture positive for NTM had a lower body mass 
index (BMI) percentile (44.3 vs 53.4, P = 0.850) and lower forced expiratory volume in 1 second 
(FEV1) percentile (81.3 vs 86.4, P = 0.286) neither was statistically significantly different. No 
difference was seen between rates of S. aureus, B. cenocepacia and B. multivorans infection 
between the two groups. There was no statistically significant difference in the incidence of CF-
related diabetes between the NTM positive and negative groups (3.8% vs 2.8%, P = 0.321). 
Following univariate analysis and step-wise logistic regression, age, P. aeruginosa, B. cepacia and 
ABPA status were incorporated into a multivariate model (Table 2 and Figure 2). In the final model 
increased age and APBA were significantly associated with NTM status with a larger effect observed 
for ABPA (age OR 1.08, 95% CI 1.06-1.11, P = 3.4x10-10 and ABPA OR 2.66, 95% CI 1.85-3.75, P = 
5.0x10-8 respectively). Intermittent, but not chronic, P. aeruginosa colonisation was also significantly 
associated (OR 1.51, 95% CI 1.14-1.99, P = 0.004). B. cepacia was not significantly associated and 
hence removed from the final parsimonious model.  
 
Incidence, prevalence and successful treatment markedly increased between 2013 and 2014 
By following individual patients through the registry longitudinally, it was possible to determine the 
incidence of new cases as a proportion. Between 2011 and 2013 approximately 40% (~26 cases per 
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year) of NTM positive individuals were new cases (Table 3 and Figure 3 a). As discussed above, a 
large increase in the overall number of NTM cases was observed between 2013 and 2014 which was 
accounted for by a large increase in the number of new cases arising that year (63% (88)). 
We then assessed the outcomes for patients who did not carryover NTM positive status into the 
following years analysis based on the registry data. Between 2010 and 2012 approximately 2 (~4%) 
patients per year cleared NTM for the duration of the study (Table 4 and Figure 3 b). In 2013 and 
2014 there was a marked increase in this number up to 16 (19.3%) and 33 patients (23.6%) 
respectively, however it is likely that some of this effect is due to the endpoint of existing data. 
 
NTM treatment appears broadly consistent with published guidelines  
From 2014 the registry began including NTM typing information from patient isolates and treatment 
information where available. For both 2014 and 2015 M. abscessus (72 [51.4%] and 55 [35.3%] 
respectively) and M. avium (16 [11.4%] and 13 [8.3%] respectively) accounted for the majority of 
known infections (Figure 4 and Supplementary Table 2). A large proportion of samples lacked 
specific typing information in 2014 (46 [32.9%]) which increased in 2015 (86 [55.1%]). 
A wide variety of therapies were employed in the treatment of NTM. Descriptive data is presented in 
Supplementary Table 3 on the different antimicrobials used. Treatments broadly followed accepted 
guidelines with amikacin preferentially used for the treatment of M. abscessus over M. avium.[4, 7] 
In a small number of cases ethambutol and rifampicin are recorded as  having been used to treat M. 
abscessus, which is not in keeping with guidance and is likely to have been ineffective. 
 
DISCUSSION 
We present data from the nationally representative UK CF Registry that show an increase in children 
and young people isolating NTM in respiratory cultures between 2010 and 2015. Over five years 
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there was a threefold increase in the prevalence of NTM positive cultures with approximately 5% of 
children and young people under 16 years of age included in the registry being NTM-positive at 
some point during the study period. M. abscessus complex and M. avium complex accounted for the 
overwhelming majority of isolates. Similar to other cohorts, age and ABPA status appeared 
significant predictors of NTM culture positivity, in addition to P. aeruginosa status.[17] 
A major strength of this study is derived from the nationally representative longitudinal source data. 
The UK CF Registry is an internationally recognised resource with greater than 90% of individuals 
with CF in the UK included in the dataset. The methodology of data collection has remained 
consistent over the time period we report, meaning that we can have confidence that reporting bias 
should not be a factor in these estimates. Secondly, this dataset allows investigation and analysis of 
the epidemiology of NTM infection specifically in children and young people under the age of 16 and 
represents the largest paediatric cohort analysed in this regard. There are important biological 
differences as CF lung disease progresses through a spectrum from the early stages in children to 
advanced disease in adults. Furthermore, children and young people receive care in paediatric 
centres that may adopt different models of care from adult centres. 
Conversely, the limitations of our study stem from the fundamental structure, as we had no direct 
control over reporting and are inherent to registry-based research. The registry does not record data 
on the frequency of sampling in patients or the sample types used. However, all UK centres 
delivering care are expected to adhere to the 2010 CF Trust guideline ‘Laboratory Standards for 
Processing Microbiological Samples from People with Cystic Fibrosis’. Furthermore, the ‘Standards 
for the Clinical Care of Children and Adults with cystic fibrosis in the UK’ document published in 2011 
states that all patients should have a respiratory sample cultured for NTM at least annually. It is 
possible however, that surveillance on only a yearly basis may lead to underestimation of the true 
prevalence. In some cases there was no recording of the individual species of NTM in the registry.  
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It is also important to state that the presence of positive respiratory cultures for NTM is not 
synonymous with NTM-PD as defined by the American Thoracic Society/Infectious Disease Society of 
America 2007 statement.[18] The diagnosis of NTM-PD requires multiple clinical criteria to be met 
and is beyond the scope of this study. 
The question of whether the increase in prevalence of NTM represents a true rise in NTM-PD in UK 
children with CF or simply represents better detection is a vexatious one. Similar questions have 
arisen in virtually every epidemiological study of infection and the data we present cannot 
fundamentally differentiate between these two possibilities. Methods to culture and detect NTM in 
respiratory samples have developed over recent years. For example, a new selective NTM growth 
medium has been demonstrated to increase sensitivity of the detection of NTM, but this is only used 
in a minority of UK CF centres.[14, 20, 21] Over the same time period reports have suggested 
possible transmission of NTM, specifically M. abscessus complex, between individuals with CF 
despite the presence of routine infection control measures in CF centres which would provide a 
potential mechanism for the observed increasing prevalence.[9, 10, 22, 23]  
Within our cohort we found associations with increasing age (OR 1.08, P = 3.4x10-10), ABPA (OR 2.66, 
P = 5.0x10-8) and P. aeruginosa status (intermittent OR 1.51, P = 0.004) and risk of NTM positive 
respiratory samples. These were consistent findings over the different annual cohorts and were also 
found in the pooled analysis of all unique individuals. Viviani et al. reported similar associations with 
age and ABPA, but not P. aeruginosa,  in multivariate analysis of European registry data from both 
children and adults with CF combined.[17]  
It is conceivable that all 3 identified risk factors in our study represent surrogate markers of 
increased lung destruction or damage which has been postulated to increase an individual’s 
vulnerability to NTM acquisition in individuals without CF.[24, 25] Advancing age is also associated 
with an inherent increase in duration of time at risk of exposure. There may also be ecological 
interactions within the lung microbiome that predispose to co-acquisition of P. aeruginosa, 
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Aspergillus species and NTM. Furthermore host immune function is likely to be relevant to these risk 
factors. In people with chronic obstructive pulmonary disease, the use of inhaled corticosteroids has 
been found to be a risk factor for NTM infection.[26] ABPA is usually treated with corticosteroids 
and it is conceivable that there is a similar association in people with CF. 
Our finding of a difference in the association between NTM status and intermittent and chronic P. 
aeruginosa status is counterintuitive. The distribution of the confidence intervals of the chronic 
status (Figure 2), however, strongly favours an effect and the overall class effect (combining both 
chronic and intermittent status) is significant. We suspect in larger populations this difference would 
likely disappear. It is worth noting that in the UK CF Registry classification of P. aeruginosa status is 
based on the number of positive respiratory samples during the last 12 months (negative, 
intermittent - defined as 1-2 isolations or chronic - defined as 3 or greater isolations), irrespective of 
whether or not the individual is maintained on chronic anti-pseudomonal suppression therapy for 
example nebulised antibiotics. 
Our results highlight that NTM infection appears to be increasing significantly in the UK paediatric CF 
population. An observation made anecdotally and expressed readily at CF clinician meetings over the 
last 5 years. These data make a compelling argument for urgent investment in research of NTM 
infection in children and young people. The advances we have seen in clinical outcomes in CF have 
largely come from innovations and improvements in paediatric CF care and similarly by addressing 
NTM infection in childhood the greatest potential gains can be made. Our data lead us to conclude 
that two areas in particular need urgent focus and collaboration. Firstly, precise, detailed 
epidemiological data on NTM infection in childhood needs to be obtained so that strategies to 
prevent acquisition can be developed. Secondly, urgent randomised trials of anti-microbial therapies 
directed against M. abscessus complex and M. avium complex in children and young people are 
required. 
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Table 1 - Summary of merged registry data 2010-2015 and univariate analysis of risk factors for NTM positive cultures 
 All NTM NTM Negative  
Variable n (%) Median (Quartiles) n (%) Median (Quartiles) n (%) Median (Quartiles) P Value 
Subjects 5,333 (100)  288 (5.4)  5,045 (94.6)   
Demographics 
Male 2,717 (50.9)  138 (47.9)  2,579 (51.1)  
0.554 
Female 2,615 (49)  150 (52.1)  2,465 (48.9)  
Age 5,333 (100) 6 (2-12) 288 (100) 10 (7-12) 5,045 (100) 6 (2-12) 2.2x10
-16
 
Height Percentile 5,110 (95.8) 112.2 (79.6-142.6) 282 (97.9) 133.9 (117.7-145.9) 4,828 (95.7) 110 (78.7-142) 0.020 
Weight Percentile 5,235 (98.2) 19.3 (10.9-34.9) 281 (97.6) 28.8 (21.5-37.6) 4,954 (98.2) 18.6 (10.6-34.7) 0.420 
BMI Percentile 3,846 (72.1) 52.8 (28.2-76.1) 262 (91) 44.3 (22.1-70.48) 3,224 (63.9) 53.48 (28.5-76.53) 0.850 
Genotype 
F508del F508del 2,704 (50.7)  164 (56.9)  2,540 (50.3)  0.418 
F508del/Other 1,968 (36.9)  89 (30.9)  1,879 (37.2)  0.452 
Other/Other 661 (12.4)  35 (12.2)  626 (12.4)  0.469 
Lung Function 
FEV1 2,541 (47.6) 1.64 (1.2-2.2) 64 (22.2) 1.5 (1.2-1.9) 2,728 (54.1) 1.7 (1.2-2.2) 0.991 
FEV1% Predicted 2,271 (42.6) 85.9 (73.4-97.5) 76 (26.4) 81.3 (68.2-94.1) 2,986 (59.2) 86.4 (74.3-97.8) 0.286 
Respiratory Microbiology 
S. aureus 1,298 (24.3)  85 (29.5)  1,213 (24)   
 Chronic 319 (6)  23 (8)  296 (5.9)  0.093 
 Intermittent 979 (18.4)  62 (21.5)  917 (18.2)  0.103 
P. aeruginosa 1,640 (30.8)  130 (45.1)  1,510 (29.9)  0.013* 
 Chronic 505 (9.5)  45 (15.6)  460 (9.1)  8.65x10
-06
 
 Intermittent 1,135 (21.3)  85 (29.5)  1,050 (20.8)  1.93x10
-05
 
B. cepacia 54 (1)  7 (2.4)  47 (0.9)  0.013 
B. cenocepacia 13 (0.2)  2 (0.7)  11 (0.2)  0.111 
B. multivorans 25 (0.5)  3 (1)  22 (0.4)  0.143 
Comorbidities 
ABPA 285 (5.3)  49 (17)  236 (4.7)  2.2x10
-16
 
CFRD 153 (2.9)  11 (3.8)  142 (2.8)  0.321 
Summary statistics for merged data. 38 data points lacking a unique identifying code were removed from the analysis, leaving a final count of 5,333 subjects. Univariate analysis comparing each factor to NTM status was performed and P values 
presented. Significant factors (highlighted) were included in the final multivariate analysis. *By Wald test, χ2 = 8.6, P = 0.013. Tested prior to inclusion in multivariate model. FEV1 – Forced expiratory volume exhaled at the end of the first second 
of forced expiration, S. aureus - Staphylococcus aureus, P. aeruginosa – Pseudomonas aeruginosa, B. cepacia - Burkholderia cepacia, B. cenocepacia - Burkholderia cenocepacia, B. multivorans - Burkholderia multivorans, ABPA - allergic 
bronchopulmonary aspergillosis, CFRD – cystic fibrosis related diabetes. 
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Table 2 – Odds ratios and significance for multivariate model 
Odds ratios, 95% CI and P values for ABPA, chronic and intermittent P. aeruginosa and age from the multivariate model are displayed. ABPA - allergic 
bronchopulmonary aspergillosis, P. aeruginosa – Pseudomonas aeruginosa. 
  
Variable Odds Ratio 95% CI P Value 
ABPA 2.656 1.854 - 3.748 5.0x10
-8
 
P. aeruginosa Intermittent 1.511 1.139 - 1.990 0.004 
P. aeruginosa Chronic 1.275 0.875 - 1.825 0.195 
Age 1.084 1.057 - 1.111 3.4x10
-10
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Table 3 – NTM origin 
Year New Cases (%) Carryover (%) Re-infection (%) Total 
2010 45 (100) 0 (0) 0 (0) 45 
2011 26 (41.9) 36 (58.1) 0 (0) 62 
2012 26 (38.2) 41 (60.3) 1 (1.5) 68 
2013 27 (32.5) 54 (65.1) 2 (2.4) 83 
2014 88 (62.9) 45 (32.1) 7 (5.0) 140 
2015 76 (48.7) 76 (48.7) 4 (2.6) 156 
Total (%) 288 (52.0) 252 (45.5) 14 (2.5) 554 
Origin of NTM cases per year, data visualised in Figure 3 a. 
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Table 4 – NTM patient outcomes 
Year 
Lost to analysis 
(%) 
Cleared for 
duration (%) 
Later re-
infection (%) 
Lost to Registry 
(%) 
Total 
2010 6 (13.3) 1 (2.2) 2 (4.4) 0 (0) 9 
2011 12 (19.4) 3 (4.8) 6 (9.7) 0 (0) 21 
2012 9 (13.2) 3 (4.4) 2 (2.9) 0 (0) 14 
2013 17 (20.5) 16 (19.3) 4 (4.8) 1 (1.2) 38 
2014 26 (18.6) 33 (23.6) 0 (0) 5 (3.6) 64 
Total 70 56 14 6 
 
NTM patient outcomes per year, data visualised in Figure 3 b. 
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FIGURE LEGENDS 
Figure 1 – NTM prevalence by year 
The prevalence of NTM in CF patients increased year on year with a particularly large increase 
observed between 2013 and 2014. Following data merge, the number of unique cases overall (288, 
5.4%) was identified. Values in brackets show percentage of individuals positive for NTM per year. 
Figure 2 – Odds ratios for multivariate model 
Odds ratios and 95% CI for ABPA, chronic and intermittent P. aeruginosa and age from the 
multivariate model are displayed. Values are shown in Table 2. 
Figure 3 – NTM origin and patient outcomes 
a) Individual patients were tracked through the registry and the source of infection graphed. A large 
increase in the total number and percentage new cases was observed between 2013 and 2014. 
Values are shown in Table 3. 
b) Patient outcomes for those who didn’t carryover NTM positive status into the following years 
analysis were also determined. A large increase in those who cleared NTM for the remainder of the 
assessment period was observed for 2013 and 2014. Values are shown in Table 4. Lost to registry 
refers to patients who should have remained available for analysis, but lacked registry data for later 
years for unknown reasons. Lost to analysis refers to patients who became older than 16 and so 
were no longer included in the analysis. 
Figure 4 – Specific strain information 2014 - 2015 
For 2014 and 2015 the registry introduced NTM typing information. Some variation between years 
was observed, especially in relation to the number of unknown cases. M. abscessus and M. avium 
accounted for the majority of cases for each year. Values shown in Table 5. 
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